Vis enkel innførsel

dc.contributor.authorHestad, Knut
dc.contributor.authorEngedal, Knut
dc.contributor.authorWhist, Jon Elling
dc.contributor.authorFarup, Per Grønaas
dc.date.accessioned2017-01-13T12:46:14Z
dc.date.available2017-01-13T12:46:14Z
dc.date.created2016-06-29T11:18:50Z
dc.date.issued2016
dc.identifier.citationNeuropsychiatric Disease and Treatment. 2016, 12 1365-1370.nb_NO
dc.identifier.issn1176-6328
dc.identifier.urihttp://hdl.handle.net/11250/2427254
dc.description.abstractIntroduction: Depression is considered an independent risk factor for hypertension, particularly for people with recurrent episodes or a long history of depression. Another risk factor for cardiovascular disease is the Apolipoprotein E e4 allele (ApoE e4). The aim of this study was to examine how ApoE e4 was related to blood pressure (BP) in patients with depression and a control group. Methods: A total of 78 patients, 49 with depression and 29 without, all recruited from the same hospital, underwent ApoE e genotyping (24 had at least one ApoE e4 allele) and examination of BP. Results: In the depression group, but not in the control group, both systolic and diastolic BP were significantly higher in patients with ApoE e4 than in those without. The effect of ApoE e4 on BP differed significantly between the two groups. Conclusion: Our findings showed that the effect of ApoE e4 on BP differed between the patients with depression and the control group. In patients with depression, ApoE e4 was associated with an increase in BP. We suggest that patients with depression and ApoE e4-positive status are particularly prone to develop BP elevation.nb_NO
dc.language.isoengnb_NO
dc.publisherDove Medical Pressnb_NO
dc.rightsNavngivelse-Ikkekommersiell 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/deed.no*
dc.titleThe effect of ApoE e4 on blood pressure in patients with and without depressionnb_NO
dc.typeJournal articlenb_NO
dc.typePeer reviewednb_NO
dc.source.pagenumber1365-1370nb_NO
dc.source.volume12nb_NO
dc.source.journalNeuropsychiatric Disease and Treatmentnb_NO
dc.identifier.doi10.2147/NDT.S106933
dc.identifier.cristin1364911
dc.description.localcode© 2016 Hestad et al. This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License ( http://creativecommons.org/licenses/by-nc/3.0 / ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms ( https://www.dovepress.com/terms.php)nb_NO
cristin.unitcode194,67,40,0
cristin.unitcode194,65,15,0
cristin.unitnamePsykologisk institutt
cristin.unitnameInstitutt for kreftforskning og molekylær medisin
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode1


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse-Ikkekommersiell 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse-Ikkekommersiell 4.0 Internasjonal